Adjuvant therapy for colorectal cancer: Present and future perspectives

Diseases of the Colon and Rectum

Volumn 40, Issue 8, 1997, Pages 977-992

  Casillas, Sergio ^a   Pelley, Robert J ^a   Milsom, Jeffrey W ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Chemotherapy; Colorectal cancer; High risk patients; Immunotherapy; Intraperitoneal infusion; Intraportal infusion; Radiotherapy

Indexed keywords

ALPHA2A INTERFERON; EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; HUMAN; PREOPERATIVE RADIOTHERAPY; REVIEW;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS;

EID: 0030846532     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02051209     Document Type: Review

References (80)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1997. CA Cancer J Clin 1997;47:5-27.
2. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 1994;81:7-19.
3. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma clue to inadequate surgical resection: histopathological study of lateral tumor spread and surgical excision. Lancet 1986;2:996-8.
4. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy for colorectal cancer, why we still don't know. JAMA 1988;259:3571-8.
5. Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer-results of a prospectively randomized trial. N Engl J Med 1984;310:737-43.
6. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
7. Steele GD, Augenlicht LH, Begg CB, et al. National Institutes of Health consensus development conference statement: adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
8. Reynolds T. Dutch trials casts doubt on colorectal adjuvant therapy. J Natl Cancer Inst 1995;87:476-80.
9. Mamounas EP, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four NSABP Adjuvant Studies (C-01, C-02, C-03, C-04) [abstract]. Proc Am Soc Clin Oncol 1996;15:205.
10. Wolmark N, Rockette H, Manounas EP, et al. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-Lev), and 5-FU + leucovorin + levamisole (FU-LV-Lev) in patients with Dukes' B and C carcinoma of the colon: first report of NSABP C-04 [abstract ]. Proc Am Soc Clin Oncol 1996;15:205.
11. Crucitti F, Sofo L, Doglietto GB, et al. Prognostic factors in colorectal cancer: current status and new trends. J Surg Oncol Suppl 1991;2:76-82.
12. Rognum TO, Thorud E, Lund E. Survival of large-bowel carcinoma patients with different DNA ploidy pattern. Br J Cancer 1987;5:633-6.
13. Takanishi D, Hart J, Covarelli P, Chappell R, Michelassi F. Ploidy as a prognostic feature in colonic adenocarcinoma. Arch Surg 1996;131:587-92.
14. Nori D, Merimsky O, Samala E, et al. Tumor ploidy as a risk factor for disease recurrence and short survival in surgically-treated Dukes' B2 colon cancer patients. J Surg Oncol 1995;59:239-42.
15. Cunningham C, Dunlop MG. Molecular genetic basis of colorectal cancer susceptibility. Br J Surg 1996;83:321-9.
16. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
17. Bardi G, Johansson B, Pandis N, et al. Cytogenetic analysis of 52 colorectal carcinomas non-random aberration pattern and correlation with pathologic parameters. Int J Cancer 1993;55:422-8.
18. Pricolo VE, Finkelstein SD, Wu TT, et al. Prognostic value of Tp53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 1996;171:41-6.
19. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994;70:293-6.
20. Tomoda H, Kakeji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J Surg Oncol 1995;58:125-8.
21. Mulder J, Baas I, Polak M, et al. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995;71:1257-62.
22. Benhattar J, Losi L, Chaubert P, et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1995;104:1044-8.
23. Finkelstein SD, Sayegh R, Baker A, Swalsky P. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-32.
24. Sinicrope F, Hart J, Brasitus T, et al. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion. DNA ploidy, and disease relapse. Cancer 1994;74:2908-17.
25. Leichman L, Lenz HJ, Leichman CG, et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-FU and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 1995;31A:1306-10.
26. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
27. MacFarlane JK, Ryall RD, Heald RG. Mesorectal excision for rectal cancer. Lancet 1993;341:457-60.
28. Wiggers T. Total mesorectal excision, a new standard for the surgical treatment of rectal carcinoma [letter]. Ned Tijdschr Geneeskd 1996;140:17.
29. Gastrointestinal Tumor Study Group. Prolongation of disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-72.
30. Grem JL, Allegra CJ. Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. J Natl Cancer Inst 1989;81:1413-6.
31. Chlebowski RT, Lillington L, Nystrom JS, Sayre J. Late mortality and levamisole adjuvant therapy in colorectal cancer. Br J Cancer 1994;69:1094-7.
32. O'Connell MJ, Laurie L, Sheperd MJ, et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group [abstract]. Proc Am Soc Clin Oncol 1996;15:209.
33. Haller DG, Catalina PJ, Macdonald JS, Macer R. Fluorouracil, leucovorin, and levamisole adjuvant therapy for colon cancer: preliminary results of INT-0089 [abstract]. Proc Am Soc Clin Oncol 1996;15:211.
34. Slevin M. Adjuvant treatment for colorectal cancer: no more room for nihilism. BMJ 1996;312:392-3.
35. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol 1990;8:1466-75.
36. Keyman HD, Robertson SH, Bloom TS, et al. Rectal carcinoma: long-term experience with moderately high-close preoperative radiation and low-anterior resection. Cancer 1992;69:2813-9.
37. Minsky BD, Cohen AM, Enker WE, Kelsen DP, Kemeny N, Frankel J. Efficacy of postoperative 5-FU, high-dose leucovorin, and sequential radiation therapy for clinically resectable rectal cancer. Cancer Invest 1995;13:1-7.
38. Sause WT, Pajak TF, Noyes RD, et al. Evaluation of preoperative radiation therapy in operable colorectal cancer. Ann Surg 1994;220:668-75.
39. Goldberg P, Nicholls R, Porter N, et al. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. Enr J Cancer 1994;30A:1602-6.
40. Marsh PJ, James RD, Sehofield PF. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma: results of a prospective randomized trial. Dis Colon Rectum 1994;37:1205-14.
41. Cedermark B, Johansson H, Rutqvist L, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. Cancer 1995;75:2269-75.
42. Gerard A, Buyse M, Nordlinger M, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606-14.
43. Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma: report from a randomized multicenter trial. Ann Surg 1990;211:187-95.
44. Swedish Rectal Cancer Trial. Five-year survival after preoperative radiation in rectal cancer [abstract]. Int J Colorectal Dis 1996;11:198.
45. Stockholm Colorectal Cancer Study Group. Randomized study on preoperative radiotherapy in rectal carcinoma. Ann Surg Oncol 1996;3:423-30.
46. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
47. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992;10:549-57.
48. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
49. Tepper I, O'Connell M, Petroni G, et al. Toxicity in the adjuvant therapy of rectal cancer: a preliminary report of Intergroup 0114 [abstract]. Proc Am Soc Clin Oncol 1996;15:210.
50. Minsky B, Cohen A, Enker W, et al. Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. Cancer 1994;73:273-80.
51. Minsky BD, Cohen AM, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992;10:79-84.
52. Boulis-Wassif S, Gerard A, Loygue J, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-FU, followed by radical surgery. Trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Cancer 1984;53:1811-8.
53. Landry JC, Koretz M, Wood WC, et al. Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma: phase I-II study. Radiology 1993;188:423-6.
54. Meterissian S, Skibber J, Rich T, et al. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol 1994;1:111-6.
55. Minsky BD, Conti JA, Huang Y, Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol 1995;13:3409-16.
56. Minsky BD, Cohen AM, Kemeny N, et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol 1992;10:1218-24.
57. Hyams DM, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. Dis Colon Rectum 1997;40:131-9.
58. Beart RW, Moertel C, Wieancl H, et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. Arch Surg 1990;125:897-901.
59. Swiss Group for Clinical Research. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995;345:349-53.
60. Fielding LP, Hittinger R, Grace RH, Fry J. Randomized controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502-6.
61. Taylor I, Rowling J, West C, et al. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985;72:359-63.
62. Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control: results of a prospective randomized clinical trial (colorectal adenocarcinoma trial). Cancer 1990;65:425-32.
63. Laffer UT, Metzger U. Intraportal chemotherapy for colorectal hepatic metastases. World J Surg 1995;19:246-51.
64. Garten L, Stenning S, Gray R. Intraportal 5-FU for colorectal cancer: the AXIS trial [letter]. Lancet 1992;340:985.
65. Sugarbaker PH, Graves T, DeBruíj́n EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 1990;50:5790-4.
66. Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW, Myers CE. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 1981;41:1916-22.
67. Graf W, Westlin JE, Pahlman L, Glimelius B. Adjuvant intraperiloneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomised phase II placebo-controlled study. Int J Colorectal Dis 1994;9:35-9.
68. Kelsen DP, Saltz L, Cohen AM, et al. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high-risk colon cancer. Cancer 1994;74:2224-33.
69. Scheithauer W, Kornek G, Rosen H, et al. Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinorna. Eur J Cancer 1995;31A:1981-6.
70. Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alpha-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1991;9:1806-10.
71. Grem JL, Jordan E, Robson ME, et al. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 1993;11:1737-45.
72. Pazdur R, Ajani JA, Patt YZ, et al. Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990;8:2027-31.
73. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alpha-2a interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
74. Seymour MT, Slevin ML, Cunningham D, et al. Randomized trial assessing the addition of interferon-a2a to 5-fluorouracil and leucovorin in advanced colorectal cancer: colorectal cancer working party of the United Kindom Medical Reserach Council. J Clin Oncol 1996;14:2280-8.
75. Reithmüller G, Schneider-Gädieke E, Schlimok G, et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994;343:1177-83.
76. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP Protocol C01. J Natl Cancer Inst 1988;80:30-6.
77. Hoover HS, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11:390-9.
78. Moertel C. Vaccine adjuvant therapy for colorectal cancer: "very dramatic" or ho-hum. J Clin Oncol 1993;11:385-6.
79. Hoover HC. Dr. Hoover responds to Dr. Moertel [letter]. J Clin Oncol 1993;11:586-95.
80. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994;86:424-30.